Pioglitazone in Treatment of Type 2 Diabetes:A Phase Ⅱ Clinical Trial

王颜刚,赵文娟,闫胜利,袁鹰,付正菊,杨军,李成乾,陈红
DOI: https://doi.org/10.3969/j.issn.1007-7669.2004.12.004
2004-01-01
Abstract:AIM: To compare the effect of pioglitazone and metformin in dereasing blood glucose, blood fat and improving insulin sensitivity. METHODS: The parallel double blind randomized control clinical trial was used. Sixty patients were divided into group A and group B. The patients of group A took metformin 500 mg, po, bid for 12 wk. The patients of group B took pioglitazone (30 mg), po, qd for (12 wk). The changes of blood glucose, blood fat and insulin before and after treatment between two groups were observed. RESULTS: Fifty-three patients (M 17,F 36; age (56±s 6) a) finished the trial. There were no differences in general data between 2 groups (P(0.05)). The blood glucose and glycosylated hemoglobin(HbA_(1c)) after treatment in two groups significantly reduced (P(0.01)). Insulin and C-peptide reduced in group B (P(0.01)). As to group A, postprandial insulin reduced (6±11) mU·L~(-1),P(0.05). The triglycerides reduced ((0.5)±(0.8)) mmol·L~(-1) and the free fat acid reduced (280±396) μmol·L~(-1) in group B. However, the high-density lipoprotein cholesterol was improved in two groups. Besides, the variable value of lower-density lipoprotein cholesterol and total cholesterol in group A was obviously lower than that in group B ((P(0.05)) or P(0.01)). Blood uric acid decreased ((27±44)) μmol·L~(-1) in group B. Both erythrocyte and hemoglobin in two groups were reduced (P(0.01)). There was no difference in adverse reaction rate between two groups (P(0.05)). CONCLUSION: Pioglitazone and metformin are equal efficient in decreasing blood glucose and regulating blood lipid. Moreover, pioglitazone exerts significant effects on improving insulin sensitivity and decreasing uric acid in blood.
What problem does this paper attempt to address?